Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kakkar, Ajay K ^a,b   Mueller, Iris ^a   Bassand, Jean Pierre ^c   Fitzmaurice, David A ^d   Goldhaber, Samuel Z ^e,n   Goto, Shinya ^f   Haas, Sylvia ^g   Hacke, Werner ^h   Lip, Gregory Y H ^d   Mantovani, Lorenzo G ⁱ   Turpie, Alexander G G ^j   van Eickels, Martin ^k   Misselwitz, Frank ^k   Rushton Smith, Sophie ^a   Kayani, Gloria ^a   Wilkinson, Peter ^l   Verheugt, Freek W A ^m  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f TOKAI UNIVERSITY   (Japan)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j MCMASTER UNIVERSITY   (Canada)

^k BAYER PHARMA AG   (Germany)

^l Wilkinson Associates   (United Kingdom)

^m Wilkinson Associates ^*  (Netherlands)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DANAPAROID; DEFIBROTIDE; DERMATAN SULFATE; DESULFATOHIRUDIN; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; RAMATROBAN; SULODEXIDE; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; ASIA; CANADA; CENTRAL AMERICA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DEMOGRAPHY; EUROPE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; REGISTER; RISK FACTOR; SOUTH AMERICA;

AGED; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RISK FACTORS; STROKE; VITAMIN K;

EID: 84877978738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063479     Document Type: Article

References (33)

1. Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, et al. (2004) Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 25: 1734-1740.
2. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, et al. (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 28: 2803-2817.
3. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, et al. (2008) Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 156: 855-863, 863 e852.
4. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27: 1979-2030.
5. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, et al. (2011) Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. The Canadian journal of cardiology 27: 74-90.
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: 2369-2429.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, et al. (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J.
8. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, et al. (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165: 1095-1106.
9. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, et al. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S.
10. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, et al. (2008) Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 29: 1181-1189.
11. Tulner LR, Van Campen JP, Kuper IM, Gijsen GJ, Koks CH, et al. (2010) Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging 27: 39-50.
12. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA, et al. (2010) The Global Registry of Acute Coronary Events, 1999 to 2009- GRACE. Heart 96: 1095-1101.
13. Antikainen RL, Moltchanov VA, Chukwuma C Sr, Kuulasmaa KA, Marques-Vidal PM, et al. (2006) Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 13: 13-29.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870.
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ, (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137: 263-272.
16. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, et al. (2012) International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 163: 13-19 e11.
17. Borzecki AM, Bridgers DK, Liebschutz JM, Kader B, Kazis LE, et al. (2008) Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc 100: 237-245.
18. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123: e269-367.
19. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY (2012) The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 107.
20. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, et al. (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26: 2422-2434.
21. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, et al. (2006) Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27: 3018-3026.
22. Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, et al. (2010) Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 123: 446-453.
23. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
24. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
25. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
26. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, et al. (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806-817.
27. Healey J, Oldgren J, Parekh A, Zhu J, Pais P,et al. Global variations in the 1-year rates of death and stroke in 15,432 patients presenting to the emergency department with atrial fibrillation in 47 countries: The RE-LY AF Registry; 2012; Munich, Germany.
28. Piccini JP, Holmes DN, Ollis DM, Fraulo ES, Thomas L, et al. (2011) Patterns of Atrial Fibrillation and Treatment Strategies Vary According to Provider Specialty Across Community Practice Settings: Findings From the ORBIT-AF Registry. Circulation 124: A16415.
29. Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, et al. (2012) Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 98: 195-201.
30. American College of Cardiology (2012) Registry data shows early patterns for new atrial fibrillation treatments [press release].
31. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
32. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
33. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.